IMP3 Mouse Monoclonal Antibody [C2-E4]
cat.: EM1701-15
| Product Type: | Mouse monoclonal IgG1, primary antibodies |
|---|---|
| Species reactivity: | Human, Mouse, Rat |
| Applications: | WB, IHC-P, IF-Cell, FC, IP |
| Clonality: | Monoclonal |
| Clone number: | C2-E4 |
| Form: | Liquid |
| Storage condition: | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage buffer: | 1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 2ug/ul |
| Purification: | Protein A affinity purified. |
| Molecular weight: | Predicted band size: 64 kDa |
| Isotype: | IgG1 |
| Immunogen: | Recombinant protein within Human IMP-3 aa 352-579 / 579. |
| Positive control: | HeLa cell lysate, 293T cell lysate, mouse placenta tissue lysate, rat placenta tissue lysate, Hela, SH-SY5Y, rat brain tissue, human liver cancer tissue, human placenta tissue, mouse testis tissue. |
| Subcellular location: | Cytoplasm. Nucleus. |
| Recommended Dilutions:
WB IF-Cell IHC-P FC IP |
1:2,000 1:50 1:50-1:200 1:50-1:100 1-2μg/sample |
| Uniprot #: | SwissProt: O00425 Human | Q9CPN8 Mouse Entrez Gene: 315697 Rat |
| Alternative names: | Cancer/testis antigen 98 CT98 DKFZp686F1078 hKOC IF2B3_HUMAN IGF II mRNA binding protein 3 IGF-II mRNA-binding protein 3 IGF2 mRNA binding protein 3 IGF2 mRNA-binding protein 3 IGF2BP3 IMP 3 IMP-3 Insulin like growth factor 2 mRNA binding protein 3 Insulin-like growth factor 2 mRNA-binding protein 3 KH domain containing protein overexpressed in cancer KH domain-containing protein overexpressed in cancer KOC 1 KOC1 VICKZ 3 VICKZ family member 3 VICKZ3 |
Images
|
Fig1:
Western blot analysis of IMP3 on different lysates with Mouse anti-IMP3 antibody (EM1701-15) at 1/2,000 dilution. Lane 1: HeLa cell lysate (20 µg/Lane) Lane 2: 293T cell lysate (20 µg/Lane) Lane 3: Mouse placenta tissue lysate (40 µg/Lane) Lane 4: Rat placenta tissue lysate (40 µg/Lane) Predicted band size: 64 kDa Observed band size: 64 kDa Exposure time: 12 seconds; ECL: K1801; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (EM1701-15) at 1/2,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1/50,000 dilution was used for 1 hour at room temperature. |
|
Fig2:
IMP3 was immunoprecipitated from 0.2 mg 293T cell lysate with EM1701-15 at 2 µg/25 µl agarose. Western blot was performed from the immunoprecipitate using EM1701-15 at 1/2,000 dilution. Anti-Mouse IgG for IP Nano-secondary antibody (NBI02H) at 1/5,000 dilution was used for 1 hour at room temperature. Lane 1: 293T cell lysate (input) Lane 2: EM1701-15 IP in 293T cell lysate Lane 3: Mouse IgG instead of EM1701-15 in 293T cell lysate Blocking/Dilution buffer: 5% NFDM/TBST Exposure time: 43 seconds |
|
Fig3: ICC staining IMP3 (green) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. |
|
Fig4: ICC staining IMP3 (green) in SH-SY5Y cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. |
|
Fig5: Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti-IMP3 antibody. Counter stained with hematoxylin. |
|
Fig6: Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-IMP3 antibody. Counter stained with hematoxylin. |
|
Fig7: Immunohistochemical analysis of paraffin-embedded human placenta tissue using anti-IMP3 antibody. Counter stained with hematoxylin. |
|
Fig8: Immunohistochemical analysis of paraffin-embedded mouse testis tissue using anti-IMP3 antibody. Counter stained with hematoxylin. |
|
Fig9: Flow cytometric analysis of HUVEC cells with IMP3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.